Search clinical trials for: MK-8266

Total 1741 results

National Institute of Allergy and Infectious Diseases...

Completed

Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048

HIV Infections

United States
Merck Sharp & Dohme LLC

Completed

Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)

Lymphoma | Solid Tumor

United States, Israel
Merck Sharp & Dohme LLC

Completed

[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)

Type 2 Diabetes Mellitus
Chinese University of Hong Kong

Recruiting

A Novel Integrative Non-invasive Embryo Selection Approach for in Vitro Fertilization Based on Artificial Intelligence Enhanced Morphokinetic Analysis and Raman Spectra in Spent Culture Media

IVF | Reproductive Issues | Subfertility

Hong Kong
Merck Sharp & Dohme LLC

Terminated

Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)

Hepatic Insufficiency | Antibacterial Agents

United States
Merck Sharp & Dohme LLC

Completed

Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)

Neoplasms | Cancer | Metastatic Solid Tumors | Locally Advanced Tumors
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003)

Hepatitis C
Merck Sharp & Dohme LLC

Terminated

Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED)

Neoplasms | Malignant
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)

Terminated

MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer

Brain and Central Nervous System Tumors

United States
Adam Brickman
National Institute on Aging (NIA)

Completed

Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults

Alzheimer Disease

United States
ALK-Abelló A/S
Merck Sharp & Dohme LLC

Completed

A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)

Rhinitis, Allergic, Perennial | Rhinitis, Allergic, Nonseasonal
Merck Sharp & Dohme LLC

Active, not recruiting

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)

Colorectal Cancer

United States, Poland, Belgium, Canada, Colombia, Costa Rica, Denmark, Estonia, France, Germany, Greece, Guatemala, Hungary, Italy, Korea, Republic of, Lithuania, Netherlands, Romania, Russian Federation, Spain, Turkey, United Kingdom
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)

Renal Impairment

United States
Tammie L. S. Benzinger, MD, PhD

Enrolling by invitation

Study of Tau Imaging With the Use of [18F]MK-6240 Tracer (MKADAD)

Alzheimer Disease

United States
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)

Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Chronic Myelomonocytic Leukemia

United States, Israel, Spain
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Influence of Hepatic Impairment on MK-8189 Treatment (MK-8189-012)

Hepatic Impairment

United States
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)

Tumor, Solid
Merck Sharp & Dohme LLC

Completed

Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)

Hepatitis C
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Completed

Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

PANCREAS | Neuroendocrine

United States
Merck Sharp & Dohme LLC

Completed

A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])

Alzheimer's Disease
Merck Sharp & Dohme LLC

Terminated

An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)

Lung Diseases | Pulmonary Disease, Chronic Obstructive
Merck Sharp & Dohme LLC

Completed

A Study of MK-0616 in Participants With Moderate Renal Impairment (MK-0616-007)

Moderate Renal Impairment

United States
Merck Sharp & Dohme LLC

Terminated

Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)

Renal Impairment

United States
Merck Sharp & Dohme LLC

Terminated

Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)

Neoplasms | Head and Neck Neoplasms | Colorectal Neoplasms

Australia, Hong Kong
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)

Renal Impairment

United States
Merck Sharp & Dohme LLC

Terminated

A Multiple Dose Titration Study of MK-8892 in Participants With Pulmonary Hypertension and Left Heart Disease (MK-8892-007)

Pulmonary Hypertension | Left Heart Disease
Chinese University of Hong Kong

Completed

MK-2206 in Recurrent Nasopharyngeal Carcinoma (MC1079)

Recurrent Nasopharyngeal Carcinoma

Hong Kong
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center; Massachusetts General Hospital; University... and other collaborators

Withdrawn

MK-2206 for Recurrent Malignant Glioma

Malignant Glioma

United States
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)

Hepatitis C
Merck Sharp & Dohme LLC

Withdrawn

The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)

Renal Insufficiency
ALK-Abelló A/S
Merck Sharp & Dohme LLC

Completed

Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)

Rhinitis, Allergic, Perennial | Rhinitis, Allergic, Nonseasonal
Merck Sharp & Dohme LLC

Completed

Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)

Chronic Hepatitis C
Suzhou Kintor Pharmaceutical Inc,

Completed

Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

Androgenetic Alopecia

United States
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

Hepatic Impairment (HI)
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-8189 in Participants With Bipolar I Disorder (MK-8189-020)

Bipolar I Disorder

United States
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

Non-segmental Vitiligo

United States, Canada, Australia, Korea, Republic of, Switzerland, Germany, Spain, Chile, France, Israel, Netherlands, Japan, Belgium, Argentina, United Kingdom
Merck Sharp & Dohme LLC

Not yet recruiting

Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)

Hepatic Insufficiency
National Human Genome Research Institute (NHGRI)

Recruiting

MK-7075 (Miransertib) in Proteus Syndrome

Proteus Syndrome

United States
Merck Sharp & Dohme LLC

Completed

A Study of Single Doses of MK -5475 on Pulmonary Vascular Resistance (MK-5475-002)

Pulmonary Arterial Hypertension

Moldova, Republic of
Merck Sharp & Dohme LLC

Completed

MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

Alzheimer's Disease

United States
Merck Sharp & Dohme LLC

Completed

The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)

Renal Insufficiency

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)

Cancer | Pharmacokinetics

Belgium
Merck Sharp & Dohme LLC

Completed

A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)

Overactive Bladder
Merck Sharp & Dohme LLC

Terminated

[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)

Alzheimer's Disease
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)

Migraine | Headache

3

Subscribe